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The complex macrophage and its role in 
inflammation
‘We can only see a short distance ahead,  
but we can see plenty there that needs to be done. ’
Alan Turing
Macrophages are a key cell type involved in all stages of 
the  inflammatory  response  and  have  diverse  functions 
that are important in the response to injury or infection 
and the resolution of inflammation. Significantly, under 
certain circumstances, macrophages can also propagate 
injury.  Macrophages  have  a  front-line  role  in  host 
defense,  where  they  respond  directly  to  microbes  and 
host danger signals far more sensitively than non-profes-
sional  innate  immune  cells.  As  professional  antigen 
present  ing cells they are also an important link between 
the  activation  and  the  coordination  of  the  adaptive 
immune system.
The  response  of  a  macrophage  to  tissue  damage  or 
pathogen insult is mediated by pattern recognition recep-
tors that trigger pathways leading to the production of 
pro-inflammatory cytokines and chemokines. Typically, 
this happens either through Toll-like receptor pathways, 
leading to production of tumor necrosis factor (TNF)-α, 
interleukin (IL)-6 and IL-12, or inflammasome-activation 
pathways,  leading  to  production  of  IL-1β  and  IL-18. 
These and other associated outputs orchestrate the influx 
of  further  inflammatory  cells  and  reactive  oxygen  and 
nitrogen  species  that  promote  microbial  killing  and 
phagocytosis.
Notably, activated macrophages can mediate inflamma-
tory diseases during, for example, an acute infection (for 
example, sepsis) or via chronic autoimmune inflamma-
tion  (such  as  atherosclerosis,  rheumatoid  arthritis  or 
glomerulonephritis). Inappropriate activation under these 
circumstances can only be understood by investi  gat  ing 
how  temporal  intracellular  and  intercellular  molecular 
behavior relates to local and systemic pheno  types. Sepsis 
remains  an  important  medical  problem,  with  high 
mortality and still no effective targeted therapies [1], so 
there is a great need for new, systems-level insights into 
how normally protective immune responses develop into 
life-threatening  diseases.  Athero  sclerosis  has  similar 
systems-level  traits,  as  a  wide  variety  of  immune  and 
metabolic  system  components  are  asso  ciated  with  the 
pathogenesis of plaques [2].
Macrophages infiltrate tissues following most forms of 
injury, including infection, ischemia and trauma, and most 
types of autoimmune inflammation, such as rheuma  toid 
arthritis,  glomerulonephritis,  diabetes  mellitus,  cardio-
vascular  disease  and  multiple  sclerosis  (for  a  recent 
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© 2011 BioMed Central Ltdreview, see [3]). Hence, they are key participants in nearly 
all forms of inflammatory injury and often function as 
regulatory  hubs  under  these  circumstances.  They  are, 
therefore, an attractive choice for in silico modeling and 
the development of computational methods targeted at 
enhancing inflammation research.
As a regulatory hub, macrophages have important roles 
in the regulation and resolution of inflammation. In skin 
wounds, switching the phenotype of infiltrating macro-
phages to express heme oxygenase 1 is associated with 
the resolution of inflammation, and inhibition of heme 
oxygenase 1 delays wound healing. Resolution of inflam-
mation also requires removal of apoptotic cells and other 
debris. Macrophage uptake of apoptotic cells, including 
neutrophils, results in an anti-inflammatory phenotype 
marked  by  production  of  IL-10,  transforming  growth 
factor (TGF)-β and anti-inflammatory lipoxins [4]. All of 
these functions provide therapeutically relevant starting 
points for developing predictive multi-scale models.
Here, we highlight the potential of in silico modeling of 
macrophage  biology  as  an  important  tool  for 
understanding  the  complexity  of  inflammatory  injury 
and repair.
The in silico macrophage
In  silico  analysis  brings  together  comprehensive  data 
from the literature and high-throughput studies. It can 
produce not only static pictures of the interactions along 
pathways, but, following conversion to a dynamic mathe-
matical  model,  can  also,  more  powerfully,  yield  a 
predictive picture of the mechanisms controlling pheno-
type. However, the caveat to this is that a model can only 
be as good as the data that are used to build it.
Statistical  analyses  of  genome-wide  transcriptional 
activity and protein abundance have been used to infer 
the critical genes and pathways involved in the response 
to specific cellular challenges (for example, [5,6]). Signifi-
cantly, however, such research synthesis efforts collect-
ively produce static relationship-based graphs with only 
tentative descriptions of pathway function. In isolation, 
such  graphs  cannot  distinguish  between  causal  and 
correlated activity. Macrophage resources have also been 
compiled and are presented in several websites [7-9]. As 
a consequence of these efforts, significant portions of the 
cellular  pathways  of  macrophages  have  been  compiled 
from  the  published  literature  and  presented  as  maps 
[10-12].  It  is  recognized,  however,  that  ensuring 
coherence  of  cell  types,  treatments,  experimental 
methods and statistically robust data across the primary 
studies is a challenge.
Developing  more  detailed  process  diagrams  of  inter-
actions [12] and implementing formal dynamic net  work 
models  (for  example,  [13])  using  time  variables  and 
canonical enzyme kinetics can enable the investigation of 
causal  pathway  dynamics.  In  this  scenario,  process 
diagrams or biochemical reaction networks can be trans-
lated  into  nonlinear  differential  equation  models 
describing temporal changes of protein or gene expres-
sion  concentrations.  It  is  important  to  note  that, 
inherently,  biological  pathways  and  their  networks  are 
nonlinear systems and, as such, their behavior cannot be 
described with a simple linear relationships between all 
components. For this reason dynamical systems model-
ing is an essential applied mathematical tool for under-
standing the behavior of complex systems over time [14]. 
Such  models  allow  a  wide  range  of  questions  to  be 
addressed,  such  as  how  the  long-term  behavior  of  the 
system depends on initial activation conditions; how the 
coordinate  regulation  of  a  biosynthesis  pathway  influ-
ences the flux of intermediate metabolites; and to what 
extent  and  how  crosstalk  between  pathways  retains 
specificity and avoids unwanted interference.
As  examples,  NF-κB  signaling  oscillation  [15],  lipid 
metabolism  [16]  and  circadian  oscillation  [17]  have  all 
been  effectively  dynamically  modeled  using  systems  of 
ordinary differential equations that are relevant to macro-
phage  function.  Directly  modeling  pathway  dynamics  is 
complicated by the need for high-quality temporal data 
describing  pathway  activity  and  high-confidence  para-
meter values, which can be directly obtained only from 
highly structured experimental data. Thus, quantitatively 
accurate  pathway  models  are  relatively  rare.  There  are 
complementary  modeling  approaches  that  minimize 
these  requirements,  such  as  logic-based  Boolean 
approaches (for a review of this approach, see [18,19]). 
However, these come with restrictions on the subtlety of 
behavior they can predict.
Several studies have modeled the macrophage at the 
level of the cell population. Its role in colonic inflamma-
tion [20], tumor growth and suppression (for example, 
[21]) and diabetes [22] have been explored in silico, and 
more speculative ideas from other fields, such as critical 
ordering in complex systems, have been explored using 
the macrophage as a test system [23].
Ultimately, in silico models could improve our under-
standing of how the molecular function of the macro-
phage  dynamically  generates  the  cellular  function  of 
macrophage activation, and this may lead to predictions 
of how best to intervene in order to modulate macro-
phage behavior (Figure 1).
The manipulated macrophage
So  far,  two  principal  approaches  have  been  taken  to 
manipulating macrophage function in vivo. The first has 
been  to  use  genetic  transduction  of  bone-marrow-
derived  cells.  Macrophages  and  their  progenitor  stem 
cells can be transduced with recombinant viruses with 
high efficiency [24]. The second approach has been to use 
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these  have  a  ‘polarizing’  effect  on  cellular  phenotype, 
resulting  in  cells  with  functional  characteristics  appro-
priate to the clinical context and the treatment required 
[25]. In the future, microRNA mimics, small molecules 
and synthetic regulatory circuits could all conceivably be 
introduced  as  therapeutic  devices  based  on  the 
predictions of in silico models (as schematically outlined 
in Figure 1).
As  well  as  being  amenable  to  ex  vivo  manipulation, 
macrophages can also preferentially localize to the site of 
injury following in vivo administration. In experimental 
immune-mediated glomerulonephritis, transduced macro-
phages  expressing  IL-4,  IL-10  or  the  IL-1  receptor 
antagonist reduced inflammation and subsequent fibrosis 
[24,26]. Macrophages expressing such anti-inflammatory 
cytokines are known as alternatively activated and the 
injection of alternatively activated macrophages has been 
used to effectively treat experimental colitis [27]. Thus, 
across  a  range  of  disease  model  settings,  exogenously 
administered  manipulated  macrophages  can  have 
beneficial therapeutic effects.
Other related types of cells may also have therapeutic 
potential - for example, myeloid-derived suppressor cells 
(MDSCs), a heterogeneous group of cells that can down-
regulate  T-cell-mediated  immune  responses.  MDSC 
activity  is  important  in  supporting  tumor  growth  [28] 
and suppressing tumor-associated immunity [29]. Thus, 
studies of MDSCs may provide insight into approaches to 
the downregulation of unwanted immune activity.
Concluding remarks and future prospects
Macrophages are highly flexible and adaptive cells of the 
immune system and are exquisitely sensitive to activation 
from a resting state by the direct sensing of pathogen and 
host  danger  signals  in  their  microenvironment.  The 
innate immune response and subsequent inflammatory 
reactions  involve  the  macrophage  initiating  a  complex 
gene  expression  program  following  activation.  In  silico 
modeling could enable studies of the molecular, genetic 
and proteomic function of the macrophage in relation to 
inflammation across multiple scales: molecular pathways 
in cell-autonomous immunity, intercellular communica-
tion  pathways  in  tissue  inflammation,  and  whole-
organism response pathways in systemic disease.
One  potential  scenario  is  depicted  in  Figure  1.  This 
illustrates  how  clinical  research  in  inflammation  and 
macro  phage  cell  biology  is  moving  towards  the  thera-
peutic clinical administration of modified macrophages 
(Figure 1a). In parallel (Figure 1b), laboratory studies are 
increasingly using high-throughput quantitative analyses 
of macrophage molecular function. Although still in its 
infancy, in silico simulation (Figure 1c) has a potentially 
key role in linking the laboratory and clinical areas by 
contributing a systems approach for precisely predicting 
the right mode of treatment to manipulate the macro-
phage  phenotype  for  maximal  therapeutic  benefit. 
Although it might seem optimistic to imagine such a role 
for in silico simulation, we would argue that this is not 
too far in the future. Such progress, however, will require 
the  refinement  of  techniques,  the  convergence  of 
Figure 1. Schematic diagram of how in silico macrophage 
modeling could be integrated with existing laboratory and 
therapeutic approaches. (a) Existing protocols can already 
reprogram patient macrophages ex vivo to treat inflammatory 
disease. Macrophages are taken from the patient; healthy 
macrophages are isolated; cytokines and/or chemokines are used to 
reprogram them; and they are then introduced back into the patient. 
(b) Laboratory investigations of high-throughput pathway-based 
analyses of multiple phenotypes are well established. The results of 
these analyses could be integrated with in silico simulations (c) to 
predict effective treatments, such as small molecules or microRNAs. 
Testing these on macrophages isolated from patients (dashed arrow) 
in an iterative manner or ‘systems loop’ could be used to validate the 
in silico model. In this way, new, personalized phenotypic markers 
and macrophage reprogramming treatments (involving a single 
modification or a combination of modifications to cells) could be 
identified, and the therapeutic potential of the ex vivo cells will 
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tion  between  disciplines  if  this  vision  is  to  become  a 
reality.
Ultimately, in silico methods could supplant the finan-
cial and ethical cost associated with experimental bench 
work.  However,  near-term  efforts  will  require  the  co-
development of experimental and in silico models, enab-
ling us to work with the underlying complexity to gain 
more insightful answers to the questions we pose than 
would be possible at the bench alone.
The opportunity is now emerging to harness in silico 
approaches to better understand macrophage biology in 
inflammatory diseases. Undoubtedly, this will accelerate 
the  future  exploitation  of  macrophage  behavior  in 
inflammatory disease.
Abbreviations
IL, interleukin; MDSC, myeloid-derived suppressor cells.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
All authors contributed to the design and writing of this commentary.
Acknowledgements
This work was supported by the Wellcome Trust (WT066784) program 
grant and BBSRC to PG. The Centre for Systems Biology at Edinburgh is a 
Centre for Integrative Systems Biology supported by the BBSRC and EPSRC 
(BB/D019621/1).
Author details
1Division of Pathway Medicine and Centre for Systems Biology Edinburgh, 
University of Edinburgh, Chancellor’s Building, Little France Crescent, 
Edinburgh EH16 4SB, UK. 2MRC Centre for Inflammation Research, University 
of Edinburgh, The Queen’s Medical Research Institute, Little France Crescent, 
Edinburgh EH16 4TJ, UK.
Published: 22 January 2011
References
1.  Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in 
hospitalization and mortality rates for severe sepsis in the United States: a 
trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250.
2.  Galkina, E, Ley K: Immune and inflammatory mechanisms of 
atherosclerosis. Annu Rev Immunol 2009, 27:165-197.
3.  McNeill E, Channon KM, Greaves DR: Inflammatory cell recruitment in 
cardiovascular disease murine models and potential clinical applications. 
Clin Sci (Lond) 2010, 118:641-655.
4.  Soehnlein O, Lindbom L: Phagocyte partnership during the onset and 
resolution of inflammation. Nat Rev Immunol 2010, 10:427-439.
5.  Mages J, Dietrich H, Lang R: A genome-wide analysis of LPS tolerance in 
macrophages. Immunobiology 2007, 212:723-737.
6.  Lacaze P, Raza S, Sing G, Page D, Forster T, Storm P, Craigon M, Awad T, Ghazal 
P, Freeman TC: Combined genome-wide expression profiling and targeted 
RNA interference in primary mouse macrophages reveals perturbation of 
transcriptional networks associated with interferon signalling. BMC 
Genomics 2009, 10:372.
7.  Lynn DJ, Winsor GL, Chan C, Richard N, Laird MR, Barsky A, Gardy JL, Roche 
FM, Chan TH, Shah N, Lo R, Naseer M, Que J, Yau M, Acab M, Tulpan D, 
Whiteside MD, Chikatamarla A, Mah B, Munzner T, Hokamp K, Hancock RE, 
Brinkman FS: InnateDB: facilitating systems-level analyses of the 
mammalian innate immune response. Mol Syst Biol 2008, 4:218.
8.  The Macrophage Community Website [http://www.macrophages.com]
9.  Severin J, Waterhouse AM, Kawaji H, Lassmann T, van Nimwegen E, Balwierz 
PJ, de Hoon MJ, Hume DA, Carninci P, Hayashizaki Y, Suzuki H, Daub CO, 
Forrest AR: FANTOM4 EdgeExpressDB: an integrated database of 
promoters, genes, microRNAs, expression dynamics and regulatory 
interactions. Genome Biol 2009, 10:R39.
10.  Raza S, McDerment N, Lacaze PA, Robertson K, Watterson S, Chen Y, Chisholm 
M, Eleftheriadis G, Monk S, O’Sullivan M, Turnbull A, Roy D, Theocharidis A, 
Ghazal P, Freeman TC: Construction of a large scale integrated map of 
macrophage pathogen recognition and effector systems. BMC Syst Biol 
2010, 4:63.
11.  Raza S, Robertson KA, Lacaze PA, Page D, Enright AJ, Ghazal P, Freeman TC: A 
logic-based diagram of signalling pathways central to macrophage 
activation. BMC Syst Biol 2008, 2:36.
12.  Oda K, Kimura T, Matsuoka Y, Funahashi A, Muramatsu M, Kitano H: Molecular 
Interaction Map of a Macrophage. AFCS Research Reports 2004, 2:14. [http://
www.afcs.org/reports/v2/DA0014/DA0014.pdf]
13.  Day J, Friedman A, Schlesinger LS: Modeling the immune rheostat of 
macrophages in the lung in response to infection. Proc Natl Acad Sci U S A 
2009, 106:11246-11251.
14.  Sauro HM: Network dynamics. Methods Mol Biol 2009, 541:269.
15.  Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, 
Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, 
Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR: Oscillations 
in NF-kappaB signaling control the dynamics of gene expression. Science 
2004, 306:704-708.
16.  Gupta S, Maurya MR, Stephens DL, Dennis EA, Subramaniam S: An integrated 
model of eicosanoid metabolism and signaling based on lipidomics flux 
analysis. Biophys J 2009, 96:4542-4551.
17.  Leloup JC, Goldbeter A: Toward a detailed computational model for the 
mammalian circadian clock. Proc Natl Acad Sci U S A 2003, 100:7051-7056.
18.  Watterson S, Ghazal P: Use of logic theory in understanding regulatory 
pathway signaling in response to infection. Future Microbiol 2010, 
5:163-176.
19.  Watterson S, Marshall S, Ghazal P: Logic models of pathway biology. Drug 
Discov Today 2008, 13:447-456.
20.  Wendelsdorf K, Bassaganya-Riera J, Hontecillas R, Eubank S: Model of colonic 
inflammation: immune modulatory mechanisms in inflammatory bowel 
disease. J Theor Biol 2010, 264:1225-1239.
21.  Owen MR, Byrne HM, Lewis CE: Mathematical modelling of the use of 
macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor 
Biol 2004, 226:377-391.
22.  Marée AF, Kublik R, Finegood DT, Edelstein-Keshet L: Modelling the onset of 
Type 1 diabetes: can impaired macrophage phagocytosis make the 
difference between health and disease? Philos Transact A Math Phys Eng Sci 
2006, 364:1267-1282.
23.  Nykter M, Price ND, Aldana M, Ramsey SA, Kauffman SA, Hood LE, Yli-Harja O, 
Shmulevich I: Gene expression dynamics in the macrophage exhibit 
criticality. Proc Natl Acad Sci U S A 2008, 105:1897-1900.
24.  Kluth DC, Ainslie CV, Pearce WP, Finlay S, Clarke D, Anegon I, Rees AJ: 
Macrophages transfected with adenovirus to express IL-4 reduce 
inflammation in experimental glomerulonephritis. J Immunol 2001, 
166:4728-4736.
25.  Wang Y, Wang YP, Zheng G, Lee VW, Ouyang L, Chang DH, Mahajan D, 
Coombs J, Wang YM, Alexander SI, Harris DC: Ex vivo programmed 
macrophages ameliorate experimental chronic inflammatory renal 
disease. Kidney Int 2007, 72:290-299.
26.  Wilson HM, Stewart KN, Brown PA, Anegon I, Chettibi S, Rees AJ, Kluth DC: 
Bone-marrow-derived macrophages genetically modified to produce 
IL-10 reduce injury in experimental glomerulonephritis. Mol Ther 2002, 
6:710-717.
27.  Hunter MM, Wang A, Parhar KS, Johnston MJ, Van Rooijen N, Beck PL, McKay 
DM: In vitro-derived alternatively activated macrophages reduce colonic 
inflammation in mice. Gastroenterology 2010, 138:1395-1405.
28.  Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of 
the immune system. Nat Rev Immunol 2009, 9:162-174.
29.  Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, 
Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, 
Bronte V: Tumor-induced tolerance and immune suppression depend on 
the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
doi:10.1186/gm218
Cite this article as: Ghazal P, et al.: The in silico macrophage: toward a better 
understanding of inflammatory disease. Genome Medicine 2011, 3:4.
Ghazal et al. Genome Medicine 2011, 3:4 
http://genomemedicine.com/content/3/1/4
Page 4 of 4